Department of Veterans Affairs, Palo Alto Health Care System, Palo Alto, CA 94304, USA.
Biochem J. 2012 May 1;443(3):757-68. doi: 10.1042/BJ20111645.
PCSK9 (proprotein convertase subtilisin/kexin type 9) plays an important role in control of plasma LDL (low-density lipoprotein) cholesterol metabolism by modulating the degradation of hepatic LDL receptor. Previous studies demonstrated that PCSK9 is a target gene of the SREBP2 [SRE (sterol-regulatory element)-binding protein 2] that activates PCSK9 gene transcription through an SRE motif of the promoter. In addition to SREBP2, HNF1α (hepatic nuclear factor 1α) positively regulates PCSK9 gene transcription in hepatic cells through a binding site located 28 bp upstream from SRE. In the present study, we have identified a novel HINFP (histone nuclear factor P) recognition motif residing between the HNF1 motif and SRE that is essential for basal and sterol-regulated transcriptions of the PCSK9 promoter. Mutation of this motif lowers the basal promoter activity and abolishes the sterol-mediated repression as well as the SREBP2-induced activation of the PCSK9 promoter. We show further that the activity of SREBP2 in stimulating PCSK9 promoter activity is greatly enhanced by HINFP. Additional experiments suggest that HINFP and its cofactor NPAT (nuclear protein of the ataxia telangectasia mutated locus) form a functional complex, and NPAT may subsequently recruit the HAT (histone acetyltransferase) cofactor TRRAP (transformation/transactivation domain-associated protein) to facilitate the histone H4 acetylation of the PCSK9 promoter. Knockdown of HINFP, NPAT or TRRAP each markedly reduces the amount of acetylated histone H4 on the PCSK9 promoter region and lowers PCSK9 protein levels. Importantly, by utilizing co-immunoprecipitation assays, we have demonstrated a direct interaction between SREBP2 and HINFP and its cofactors NPAT/TRRAP. Taken together, these new findings identify HINFP as a co-activator in SREBP-mediated transactivation of PCSK9 gene expression.
PCSK9(前蛋白转化酶枯草溶菌素 9)通过调节肝内 LDL 受体的降解,在控制血浆 LDL(低密度脂蛋白)胆固醇代谢中发挥重要作用。先前的研究表明,PCSK9 是 SREBP2 的靶基因,后者通过启动子中的 SRE 基序激活 PCSK9 基因转录。除了 SREBP2 之外,HNF1α(肝核因子 1α)通过位于 SRE 上游 28bp 的结合位点正向调节肝细胞中 PCSK9 基因转录。在本研究中,我们鉴定了一个位于 HNF1 基序和 SRE 之间的新的 HINFP(组蛋白核因子 P)识别基序,该基序对于 PCSK9 启动子的基础转录和固醇调节转录至关重要。该基序的突变降低了基础启动子活性,并消除了固醇介导的抑制以及 SREBP2 诱导的 PCSK9 启动子激活。我们进一步表明,HINFP 极大地增强了 SREBP2 刺激 PCSK9 启动子活性的能力。额外的实验表明,HINFP 及其共因子 NPAT(共济失调毛细血管扩张症突变基因的核蛋白)形成一个功能性复合物,NPAT 随后可能募集 HAT(组蛋白乙酰转移酶)共因子 TRRAP(转化/转导结构域相关蛋白),以促进 PCSK9 启动子的组蛋白 H4 乙酰化。HINFP、NPAT 或 TRRAP 的敲低均显著降低 PCSK9 启动子区域组蛋白 H4 的乙酰化水平,并降低 PCSK9 蛋白水平。重要的是,通过共免疫沉淀测定,我们证明了 SREBP2 与 HINFP 及其共因子 NPAT/TRRAP 之间的直接相互作用。总之,这些新发现确定 HINFP 是 SREBP 介导的 PCSK9 基因表达转录激活的共激活因子。